RSC Advances
Paper
with CH2Cl2 until the rst blue eluate was obtained, then with Maj/Min ratio ¼ 56 : 44) d (ppm): 8.73 (s, 1H, Maj), 8.66 (s, 1H,
the CH2Cl2 : ethyl acetate 9 : 1. The collected fractions were Min), 8.35 (s, 1H, Min), 7.90 (s, 1H, Maj), 3.72–3.33 (m, 8H, Maj
1
concentrated in vacuo and analyzed through H NMR and 13C + Min), 2.14–1.94 (m, 8H, Maj + Min); 13C NMR: (150.8 MHz,
NMR, and mass spectrometry. The NMR analysis indicated CDCl3, 25 ꢀC) d (ppm): 172.8, 172.7, 156.8 (CH), 154.9 (CH),
presence of two species. Many attempts to obtain crystals suit- 151.3, 145.0, 138.6, 137.9, 130.3, 128.6 (CH), 127.9, 125.6, 125.0,
able for X-ray diffraction analysis failed. The mixture was sub- 124.9 (CH), 113.9, 113.3, 109.2, 106.0, 50.6 (NCH2, 2 broad
jected to preparative TLC and the two separated spot were signals overlapped), 29.7 (NCH2CH2), 25.6 (NCH2CH2); HRMS
scraped but, once each was dissolved in CD3CN to be analyzed, (ESI+) m/z: [M + H]+ calcd for C13H11N6O6S+: 379.0455; found:
the 1H NMR revealed presence of a mixture of two compounds 379.0466.
in relative ratio equal to that found prior to separation. Thus,
below we report the physico-chemical data of the mixture of
isomers and, due to the presence of two isomers, we considered
Synthesis of 7-(2-dialkylaminothiazol)-4,6-dinitrobenzo[c]
[1,2,5]oxadiazoles
sufficient to record ESI-MS data. In particular, when, from the
1H NMR spectrum, it was evident that the two species were
General procedure. To a solution of ClDNBZ (0.018 g, 0.074
present in different amount, we indicated as Maj or Min the mmol) in acetonitrile (9 mL) 0.028 g of 3a (or 3b, or 3c) (0.165,
signals of the isomer present in major or minor amount, 0.167, 0.182 mmol, respectively) were added. Immediately aer
respectively. On the basis of the analysis derived from experi- the reagents mixture, the colour of the solution turned blue.
mental data/DFT calculations, below we report the names of the The reaction was carried out at room temperature and under
isomers attributing structure A0 to 5c and A to 50c, and assuming magnetic stirring, and the conversion was monitored through
analogous behaviour also for cases a and b.
TLC analysis (eluent: CH2Cl2). Aer 4 h, 3 h and 2 h, for the
reaction with 3a, 3b, or 3c, respectively, the solvent was removed
7-(2-Morpholinothiazol-5-yl)-4,6-dinitrobenzo[c][1,2,5]oxa-
diazole 1-oxide (5a) and 4-(2-morpholinothiazol-5-yl)-5,7-dini- in vacuo and the crude residue was chromatographed on silica
trobenzo[c][1,2,5]oxadiazole 1-oxide (50a). Dark blue solid, gel column eluting with CH2Cl2 giving pure substitution
0.008 g, 24% yield; 1H NMR (300 MHz, CD3CN, 25 ꢀC, isomeric compounds 8a–c. Compound 8c was obtained also from
Maj (50a)/Min (5a) ratio ¼ 67 : 33) d (ppm): 8.73 (s, 1H, Maj), 8.47 reduction of the isomeric mixture 5c/5c0 with P(Ph)3 in xylene
(s, 1H, Min), 8.32 (s, 1H, Min), 7.71 (s, 1H, Maj), 3.85–3.75 (m, using the procedure already reported of reduction of benzo-
1
8H, Maj + Min), 3.67–3.59 (m, 8H, Maj + Min); H NMR (399.9 furoxans to benzofurazans.55
ꢀ
MHz, CDCl3, 25 C, isomeric Maj/Min ratio ¼ 50 : 50) d (ppm):
4-(2-Morpholinothiazol-5-yl)-5,7-dinitrobenzo[c][1,2,5]oxa-
8.69 (s, 1H), 8.65 (s, 1H), 8.24 (s, 1H), 7.79 (s, 1H), 3.89–3.84 (m, diazole (8a). Dark blue solid, 0.007 g, 25% yield. 1H NMR: (599.7
8H), 3.78–3.74 (m, 4H), 3.71–3.67 (m, 4H); 13C NMR: (150.8 MHz, CD3CN, 25 ꢀC) d (ppm): 8.80 (s, 1H), 8.78 (s, 1H), 3.83–3.80
MHz, CDCl3, 25 C) d (ppm, selected data): 176.0, 175.9, 154.9 (m, 4H), 3.77–3.73 (m, 4H); 13C NMR: (150.8 MHz, CD3CN, 25
ꢀ
(CH), 152.1 (CH), 151.1, 144.6, 139.5, 132.4, 127.9 (CH), 125.0, ꢀC) d (ppm): 177.4, 157.1 (CH), 151.4, 144.3, 130.1, 130.0, 127.7
124.6, 124.2 (CH), 113.5, 113.3, 108.6, 105.8, 66.0 (OCH2), 65.9 (CH), 126.1, 116.3, 66.5 (OCH2), 49.8 (NCH2); HRMS (ESI+) m/z:
(OCH2), 48.9 (NCH2), 48.8 (NCH2); ESI-MS (m/z): 393 (M ꢁ H)ꢁ; [M + H]+ calcd for C13H11N6O6S+: 379.0455; found: 379.0466.
HRMS (ESI+) m/z: [M + H]+ calcd for C13H11N6O7S+: 395.0404;
found: 393.0412.
5,7-Dinitro-4-(2-(piperidin-1-yl)thiazol-5-yl)benzo[c][1,2,5]
1
oxadiazole (8b). Green-blue solid, 0.006 g, 22% yield. H NMR
ꢀ
4,6-Dinitro-7-(2-(piperidin-1-yl)thiazol-5-yl)benzo[c][1,2,5]
(300.0 MHz, CD3CN, 25 C) d, ppm: 8.90 (s, 1H), 8.79 (s, 1H),
oxadiazole 1-oxide (5b) and 5,7-dinitro-4-(2-(piperidin-1-yl) 3.83–3.73 (m, 4H), 1.80–1.70 (m, 6H); 1H NMR (599.7 MHz,
thiazol-5-yl)benzo[c][1,2,5]oxadiazole 1-oxide (50b). Night blue CDCl3, 25 ꢀC) d, ppm: 9.06 (s, 1H), 8.79 (s, 1H), 3.79 (br. s, 4H),
1
13
ꢀ
ꢀ
solid, 0.010 g, 29% yield. H NMR: (599.7 MHz, CDCl3, 25 C, 1.79 (br. s, 6H); C NMR: (150.8 MHz, CDCl3, 25 C) d, ppm:
isomeric Maj (50b)/Min (5b) ratio ¼ 56 : 44) d (ppm): 8.79 (s, 1H, 176.1, 159.3 (CH), 149.9, 142.9, 136.7, 129.1 (CH), 128.3, 125.4,
Maj), 8.71 (s, 1H, Min), 8.29 (s, 1H, Maj), 7.94 (s, 1H, Min), 3.80– 116.3, 50.7 (br. s. NCH2), 25.5 (NCH2CH2), 23.8 (NCH2CH2CH2);
3.73 (m, 4H, Min), 3.73–3.68 (m, 4H, Maj), 1.83–1.73 (m, 12H, HRMS (ESI+) m/z: [M + H]+ calcd for C14H13N6O5S+: 377.0663;
Maj + Min); 13C NMR: (150.8 MHz, CDCl3, 25 ꢀC) d (ppm): 176.1, found: 377.0680.
175.8, 157.1 (CH), 155.1 (CH), 151.3, 145.0, 138.6, 138.0, 130.4,
128.7 (CH), 127.9, 125.4, 125.0, 124.9 (CH), 113.8, 113.3, 109.4, oxadiazole (8c). Dark blue solid, 0.004 g, 15% yield. H NMR:
5,7-Dinitro-4-(2-(pyrrolidin-1-yl)thiazol-5-yl)benzo[c][1,2,5]
1
ꢀ
105.9, 50.5 (NCH2, 2 signals overlapped), 25.4 (NCH2CH2), 23.8 (599.7 MHz, CD3CN, 25 C) d (ppm): 8.94 (s, 1H), 8.80 (s, 1H),
(NCH2CH2CH2), 23.7 (NCH2CH2CH2); HRMS (ESI+) m/z: [M + 4.00–3.33 (br. m, 4H), 2.15–2.10 (br. m, 4H); 13C NMR: (150.8
H]+ calcd for C14H13N6O6S+: 393.0612; found: 393.0632.
MHz, CD3CN, 25 C) d (ppm): 174.0, 159.4 (CH), 151.4, 144.4,
ꢀ
4,6-Dinitro-7-(2-(pyrrolidin-1-yl)thiazol-5-yl)benzo[c][1,2,5]
138.1, 130.5 (CH), 129.4, 126.4, 116.8, 51.8 (br. s. NCH2), 26.1
oxadiazole 1-oxide (5c) and 4-(2-morpholinothiazol-5-yl)-5,7- (br. s, NCH2CH2); HRMS (ESI+) m/z: [M + H]+ calcd for
dinitrobenzo[c][1,2,5]oxadiazole 1-oxide (50c). Brilliant dark
C
13H11N6O5S+: 363.0506; found: 363.0513.
green shiny, 0.019 g, 57% yield. 1H NMR: (400 MHz, CDCl3,
Reactions between 1–3 and DNBF (10). Formation of Ma–Mc
ꢀ
25 C, isomeric Maj (50c, or A)/Min (5c, or A0) ratio ¼ 59 : 41) (experimental details on variable temperature NMR reactions
d (ppm): 8.81 (s, 1H, Maj), 8.71 (s, 1H, Min), 8.28 (s, 1H, Maj), are reported in ESI†).
7.96 (s, 1H, Min), 4.00–3.35 (m, 8H, Maj + Min), 2.27–2.03 (m,
(7-(2-Morpholinothiazol-5-yl)-6-nitro-1-oxidobenzo[c][1,2,5]
1
8H, Maj + Min); H NMR: (300 MHz, CD3CN, 25 C, isomeric oxadiazol-4(7H)-ylidene)azinate (Ma). 1H NMR: (399.9 MHz,
ꢀ
34678 | RSC Adv., 2020, 10, 34670–34680
This journal is © The Royal Society of Chemistry 2020